ArticleClinical and experimental nephrology2025
Stellate ganglion light irradiation to enhance vasodilation in arteriovenous fistula creation for hemodialysis.
Article in Clinical and experimental nephrology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAchieving functional arteriovenous fistulas (AVFs) with sustained patency in chronic kidney disease (CKD) patients remains challenging. Preoperative vessel diameter and early postoperative blood flow are key determinants of AVF maturation. While regional anesthesia promotes vasodilation, it carries procedural risks and requires specialized expertise. Stellate ganglion light irradiation (SG-LI) using near-infrared light (NIR) is a minimally invasive alternative for vasodilation. We evaluated the safety, feasibility, and vasodilatory effects of SG-LI for AVF creation in CKD patients.
methodsThis pilot study was prospectively registered (jRCT1032230550) and enrolled adult CKD patients scheduled for elective AVF creation at Kameda Medical Center in Japan between January and March 2024. SG-LI was performed preoperatively using a near-infrared therapy device. Ultrasound measured vessel diameters before and after SG-LI. The primary outcome was the diameter change in cephalic vein. Secondary outcomes included diameter changes in the median cubital vein, communicating vein, radial artery, and brachial artery. Adverse events and AVF patency at one and six months were also assessed.
resultsSG-LI significantly increased vessel diameters in the cephalic vein (0.29 ± 0.23 mm, p = 0.034), median cubital vein (1.06 ± 0.80 mm, p = 0.002), and brachial artery (0.22 ± 0.27 mm, p = 0.034). No significant changes were observed in the radial artery (0.09 ± 0.16 mm, p = 0.108) or communicating vein ( - 0.014 ± 0.45 mm, p = 0.613). No adverse events occurred. AVF patency was 100% at one and six months.
conclusionsSG-LI is a safe, feasible, and minimally invasive modality that induces vasodilation in CKD patients. It may offer an alternative to regional anesthesia for AVF creation.
trial registrationThis study was prospectively registered on Japan Registry of Clinical Trials (jRCT1032230550).
Indexed as
Identifiers
40593391What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.